Many people are still wondering why there is no cure for cancer. Researchers have joined scientists in the search for a cure. While they have made some progress, there are some challenges in finding the cure since cancer is a string on many diseases divided into different sub-types. Therefore, cancer research is a slow process that requires the input of skilled scientists as well as donors. That is where Tempus comes in. Headed by Eric Lefkofsky, Tempus is a firm that uses technology to generate data in order to assist in personalizing cancer therapy while improving patient care by maximizing efficiency. Recently, the company received a donation of $80 million from investors.
Since it was established, Tempus has received $210 million investment. Aside from that, the recent funding makes it one of the leading firms dedicated to coming up with data-driven technology to help patients battle this disease. Today, the firm’s value is approximated to be about $1.1 billion.
Offering Employment Opportunities
Tempus is an equal employer. It is thinking of adding more employees to its management. According to Eric Lefkofsky, it is reasonable to hire 30 workers per month. He also added that the pace is expected to rise since the company uses funds to expand the firm’s portfolio of services.
Tempus Applies Clinical Data for Treatment
Tempus is applying clinical data to discover different trends in the therapy as well as the management of cancer symptoms. It is also collecting data from different patients who are undergoing treatment. In some cases, Lefkofsky says, the data collection entails digitizing a medical practitioner’s handwritten notes for them to be searchable and stored to better treatment options.
Outline and Review
With that said, Eric Lefkofsky is dedicated to ensuring that cancer patients receive viable management options for their conditions.
To Learn More Click Here